Media Release Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxel Ongoing complete response has been maintained since the patient started treatment with efti monotherapy Efti + paclitaxel combination continues to be well tolerated with a favourable safety profile First-ever 90mg dosing leads to higher maximum concentration of efti, as well as pharmacologically active level up to 96 h ...

文章核心观点 - 公司开展了一项EFTISARC-NEO II期临床试验,评估efti联合放疗和抗PD-1疗法治疗软组织肉瘤的疗效和安全性[1][2][3][4] - 该试验是首次在术前评估efti的疗效,结果显示4/6例患者(67%)达到近完全病理学反应,这在标准治疗中很少见[3][4] - 该疗法安全性良好,未发现新的安全问题[3] - 公司表示如果这一积极趋势持续,将尽快推进这一创新疗法惠及软组织肉瘤患者[4] 行业概况 - 软组织肉瘤是一种罕见且预后较差的疾病,存在较大的未满足医疗需求[7][8] - 欧洲每年约23,400例新发病例,美国每年约13,400例新发病例[8] 公司概况 - 公司是一家临床阶段生物技术公司,专注于开发LAG-3免疫疗法用于治疗癌症和自身免疫疾病[10] - 公司在LAG-3领域拥有丰富的研究经验和多元化的产品管线[10]

Immutep Limited宣布TACTI-003（KEYNOTE-PNC-34）第IIb期试验的初步顶线结果 - efti与MSD的PD-1疗法在头颈鳞状细胞癌患者中显示出26.9%的整体反应率[2] - efti与KEYTRUDA®的组合可能改善患者的临床反应，并扩大对后者的反应人群[3]

试验计划 - CHDR将进行IMP761的第一阶段试验，旨在评估其对免疫系统恢复平衡和治疗自身免疫疾病的效果[1] 产品介绍 - IMP761是一种首创的LAG-3激动剂抗体，旨在通过抑制自身抗原特异性记忆T细胞的活性，从而治疗多种自身免疫疾病[3] - IMP761具有潜力通过沉默在疾病部位积累的自身免疫记忆T细胞，恢复免疫系统平衡，治疗多种自身免疫疾病[4]

SYDNEY, AUSTRALIA, April 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive feedback from the Spanish Agency for Medicines and Health Products (AEMPS) Competent Authority regarding the Company's upcoming TACTI-004 Phase III trial of eftilagimod alpha ("efti") for first line treatment of metastatic non-small ...

Exhibit 99.1 IMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Half-Year Financial Report For the Half-Year Ended 31 December 2023 (previous corresponding period: half-year ended 31 December 2022) To be read in conjunction with the 30 June 2023 Annual Report. In compliance with Listing Rule 4.2A. ABN 90 009 237 889 ASX/Media Release (ASX: IMM) 28 February 2024 Appendix 4D Half-Year Financial Report Results for Announcement to the Market Current Reporting Period – Half-year Ended 31 December 2023 Previous Repor ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION ...

Exhibit 99.1 ASX/Media Release Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer • Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not been reached in patients with high PD-L1 expression (TPS >50%), exceeding expectations • Promising Overall Surviv ...

Exhibit 99.1 IMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Half-Year Financial Report For the Half-Year Ended 31 December 2022 (previous corresponding period: half-year ended 31 December 2021) To be read in conjunction with the 30 June 2022 Annual Report. In compliance with Listing Rule 4.2A. ABN 90 009 237 889 ASX/Media Release (ASX: IMM) 24 February 2023 Appendix 4D Half-Year Financial Report Results for Announcement to the Market Current Reporting Period – Half-year Ended 31 December 2022 Previous Repor ...